US FDA asks for additional study of TiGenix's ChondroCelect

The US FDA has requested an additional clinical trial of TiGenix's cartilage re-generation product ChondroCelect before it can be approved, the company has said.

The US FDA has requested an additional clinical trial of TiGenix's cartilage re-generation product ChondroCelect before it can be approved, the company has said.

ChondroCelect is used to repair defects in the cartilage of the femoral condyle (the end of the thighbone) in the...

Welcome to Scrip

Create an account to read this article

More from New Products

Sanofi’s Inhibrx-Acquired Rare Disease Therapy Clears Phase II Hurdle

 
• By 

Efdoralprin alfa, which was acquired through Inhibrx, has met the endpoints of a Phase II trial for alpha-1 antitrypsin deficiency.

Pipeline Watch: Two Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Phase III Success For AiCuris’s Herpes Simplex Treatment

 

The German company is now gearing up for a US filing for a product that overcomes drug resistance issues in herpes simplex, and which it believes could transform its business.

Pipeline Watch: Five Approvals And Eight Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Sponsored by :

Podcast: Innovating Autoimmune Treatment with In Vivo CAR-T

As in vivo CAR-T therapy nears clinical use, researchers and industry leaders explore how it could transform autoimmune disease treatment. Novotech’s Pete Robinson joins Citeline’s Meredith Landry to discuss the science, strategy, and partnerships shaping the future of cell therapy.

How To Score A Win With Real-World Evidence In India

 
• By 

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By 

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.